Clinical studies have illustrated that FABP5 overexpression is closely linked with poor clinical outcomes in HCC, colorectal cancer, and breast cancer, and it has emerged as a key oncogenic driver in liver tumorigenesis (54). Here, FABP5 is linked to hepatocellular carcinoma.